A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension

References

• Aessopos A, Stamatelos G, Skoumas V, et al. (1995). Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest 107:50–3.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Bodin F, Channick RN, et al. (2002). Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Ther Res 63:227–46.
   Web of Science ®Google Scholar
• Badesch DB, Hill NS, Burgess G, et al. (2007). Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417–22.
   PubMed Web of Science ®Google Scholar
• Badesch DB. (2000). Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–34.
   PubMed Web of Science ®Google Scholar
• Barst RJ, et al. (2006). Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049–56.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A, et al. (2004). Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441–7.
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. (2003). Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–25.
   PubMed Web of Science ®Google Scholar
• Barst RJ, et al. (1996). A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301.
   PubMed Web of Science ®Google Scholar
• Casanova C, Celli BR, Barria P, et al. (2011). The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 37:150–6.
   PubMed Web of Science ®Google Scholar
• Channick R, Badesch DB, Tapson VF, et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 20:262–1123.
   Google Scholar
• Chin KM, Ruggiero R, Bartolome S, et al. (2015). Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center. Pulm Circ 5:513–20.
   PubMed Web of Science ®Google Scholar
• Cottin V, Le Pavec J, Prevot G, et al. (2010). Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35:105–11.
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE. (1991). Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343–9.
   PubMed Web of Science ®Google Scholar
• Duarte JD, Hanson RL, Machado RF. (2013). Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol 9:335–49.
   PubMedGoogle Scholar
• Duo-Ji MM, Long ZW. (2017). Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: a network meta-analysis. Int J Cardiol 234:90–8.
   PubMed Web of Science ®Google Scholar
• Elliott JD, Ohlstein EH, Peishoff CE, et al. (1998). Endothelin receptor antagonists. Pharm Biotechnol 11:113–29.
   PubMedGoogle Scholar
• Farber HW, Loscalzo J. (2004). Pulmonary arterial hypertension. N Engl J Med 351:1655–65.
   PubMed Web of Science ®Google Scholar
• Galie N, et al. (2015a). Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373:834–44.
   PubMed Web of Science ®Google Scholar
• Galie N. (2006). Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48–54.
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, et al. (2009a). Tadalafil therapy for pulmonary arterial hypertension. Circulation 119: 2894–903.
   PubMed Web of Science ®Google Scholar
• Galie N, Corris PA, Frost A, et al. (2013). Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62:D60–72.
   PubMed Web of Science ®Google Scholar
• Galie N, et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–57.
   PubMed Web of Science ®Google Scholar
• Galie N, et al. (2009b). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–537.
   PubMed Web of Science ®Google Scholar
• Galie N, et al. (2002). Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–502.
   PubMed Web of Science ®Google Scholar
• Galie N, Müller K, Scalise A-V, et al. (2015b). Patent plus: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 45:1314–22.
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, et al. (2008a). Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010–9.
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin LJ, Hoeper MM, et al. (2008b). Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371:2093–100.
   PubMed Web of Science ®Google Scholar
• Gao X-F, Zhang J-J, Jiang X-M, et al. (2017). Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. Ppa 11:871–85.
   Web of Science ®Google Scholar
• Ghofrani H-A, Galie N, Grimminger F, et al. (2013). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–40.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Sullivan MJ, Thompson PJ, et al. (1985). The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132:919–23.
   PubMed Web of Science ®Google Scholar
• Hiremath J, Thanikachalam S, Parikh K, et al. (2010). Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 29:137–49.
   PubMed Web of Science ®Google Scholar
• Hoendermis ES, Liu LCY, Hummel YM, et al. (2015). Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36:2565–73.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, et al. (2006a). Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28:691–4.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, et al. (2006b). Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28:691–4.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. (2004). Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24:353–9.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Inoue S, Ishii T, et al. (2016). Comparative effectiveness of oral medications for pulmonary arterial hypertension. Int Heart J 57:466–72.
   PubMed Web of Science ®Google Scholar
• Iversen K, Jensen AS, Jensen TV, et al. (2010). Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 31:1124–31.
   PubMed Web of Science ®Google Scholar
• Jain S, Khera R, Girotra S, et al. (2017). Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest 151:90–105.
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Parikh K, Pulido T, et al. (2013). Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 127:624–33.
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Yu Z-X, Shen J-Y, et al. (2011). Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 183:1723–9.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Berghold A, Scheidl S, et al. (2009). Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34:888–94.
   PubMed Web of Science ®Google Scholar
• Lasker GF, Maley JH, Pankey EA, et al. (2011). Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Rev Respir Med 5:153–61.
   PubMed Web of Science ®Google Scholar
• Lin H, Wang M, Yu Y, et al. (2018). Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: a network meta-analysis. Pulm Pharmacol Ther 50:1.
   PubMed Web of Science ®Google Scholar
• McGoon MD, Benza RL, Escribano-Subias P, et al. (2013). Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62:D51–9.
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Channick RN, Ghofrani H-A, et al. (2015). Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 46:405–13.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. (2010). Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. A randomized controlled clinical trial. J Am Coll Cardiol 55:1915–22.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Gaine SP, Barst RJ, et al. (2003). Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293–9.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, et al. (2006). Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174:1257–63.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Ejiri K, Matsubara H. (2014). Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118:414–9.
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Schilz RJ, Barst RJ, et al. (2004). Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420–7.
   PubMed Web of Science ®Google Scholar
• Paradis NA, Martin GB, Goetting MG, et al. (1989). Simultaneous aortic, jugular bulb, and right atrial pressures during cardiopulmonary resuscitation in humans. Insights into mechanisms. Circulation 80:361–8.
   PubMed Web of Science ®Google Scholar
• Prins KW, Thenappan T. (2016). World Health Organization Group I Pulmonary Hypertension: epidemiology and pathophysiology. Cardiol Clin 34:363–74.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–18.
   PubMed Web of Science ®Google Scholar
• Reddy S, Fung A, Manlhiot C, et al. (2015). Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy . Pediatr Res 77:363–9.
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Ghofrani H-A, Beghetti M, et al. (2015). Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 101:1792–9.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. (1997). Primary pulmonary hypertension. N Engl J Med 336:111–7.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Galie N, Grimminger F, et al. (2015). Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 45:1303–13.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. (1990). Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485–91.
   PubMed Web of Science ®Google Scholar
• Sandoval J, Torbicki A, Souza R, et al. (2012). Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 25:33–9.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Rubin LJ, et al. (2004). Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S.
   PubMed Web of Science ®Google Scholar
• Simonneau G. (2008). Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 149:521–30.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. (2012). Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40:874–80.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. (2015). Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373:2522–33.
   PubMed Web of Science ®Google Scholar
• Taichman DB, McGoon MD, Harhay MO, et al. (2009). Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc 84:586–92.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing Z-C, Xu K-F, et al. (2013). Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 144:952–8.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. (2012). Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 142:1383–90.
   PubMed Web of Science ®Google Scholar
• Vizza CD, Jansa P, Teal S, et al. (2017). Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord 17:239.
   PubMed Web of Science ®Google Scholar
• von Leupoldt A, Ambruzsova R, Nordmeyer S, et al. (2006). Sensory and affective aspects of dyspnea contribute differentially to the Borg scale’s measurement of dyspnea. Respiration 73:762–8.
   PubMed Web of Science ®Google Scholar
• Webb DJ, Vachiery J-L, Hwang L-J, et al. (2015). Sildenafil improves renal function in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 80:235–41.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, et al. (2005). Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 171:1292–7.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li X, Huang J, et al. (2016). Comparative efficacy and safety of prostacyclin analogs for pulmonary arterial hypertension: a network meta-analysis. Medicine (Baltimore) 95:e2575.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Jiang B, Gao H, et al. (2014). Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res 37:507–12.
   PubMed Web of Science ®Google Scholar